Sign In
Buy ILMN
$161.38
-0.550 (-0.340%)
At Close: Jun 22, 2026
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
09:05am, Tuesday, 23'rd Jun 2026
Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's Board SAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc.
The Healthcare M&A Wave
12:30pm, Wednesday, 17'th Jun 2026
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
10:50am, Wednesday, 17'th Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Illumina (ILMN) is a Top Growth Stock for the Long-Term
10:47am, Thursday, 11'th Jun 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Illumina (ILMN): Bullish Structure Builds After Breakout
05:10pm, Tuesday, 09'th Jun 2026
Illumina maintains a long-term bullish reversal after breaking out of an inverse head and shoulders pattern, with key support holding as upside targets remain in focus.
Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
09:15am, Monday, 08'th Jun 2026
StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundaries Whole-transcriptome profiling across a large tissue capture area can gener
Skip the Oura Ring IPO. Buy These 10 Stocks Instead.
12:00am, Friday, 05'th Jun 2026
Oura Ring's IPO looks like Peloton in 2020 - great product, dangerous price. Ten public wellness stocks own the real trade.
Is Grail Stock a Bad-News Buy After Its Recent Pullback?
12:15pm, Thursday, 04'th Jun 2026
The cancer test maker could still have a bright future.
ILMN Stock Jumps 98.7% in a Year: What's Powering the Surge?
11:55am, Wednesday, 03'rd Jun 2026
Illumina shares surge 98.7% in a year as NovaSeq X adoption accelerates, clinical sequencing demand grows, and the company tops Q1 2026 guidance.
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
01:10pm, Tuesday, 02'nd Jun 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
08:58am, Monday, 01'st Jun 2026
BOULDER, Colo.--(BUSINESS WIRE)-- #ArcherAnalysis--IDT's library prep solutions join Illumina's extensive software ecosystem to enable streamlined analysis for IDT's FFPE and cfDNA workflows.
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
12:30pm, Thursday, 28'th May 2026
Automating library prep reduces hands-on time for customers using Pillar Biosciences oncoReveal® targeted oncology research panels SAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN
Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
09:15am, Thursday, 28'th May 2026
An advanced research workflow for fast, flexible detection of molecular residual disease during and following treatment Solution is the first in a new WGS oncology portfolio, building on Illumina's hi
Here's Why Illumina (ILMN) is a Strong Momentum Stock
10:50am, Wednesday, 27'th May 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Illumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy?
10:46am, Tuesday, 26'th May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
